GeneDx Holdings Corp.
WGS
$107.37
-$0.985-0.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 50.26% | 52.07% | 54.43% | 31.73% | 3.66% |
| Total Other Revenue | -13.79% | -52.01% | -52.36% | -39.62% | -16.37% |
| Total Revenue | 48.70% | 48.81% | 50.79% | 29.41% | 3.06% |
| Cost of Revenue | 9.90% | 3.71% | -2.15% | -34.14% | -46.84% |
| Gross Profit | 79.69% | 93.63% | 118.16% | 277.05% | 311.51% |
| SG&A Expenses | 12.20% | 3.38% | -11.86% | -26.98% | -39.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -36.81% | -51.05% | -68.39% | -75.00% | -57.19% |
| Total Operating Expenses | 10.84% | 0.84% | -10.42% | -31.87% | -41.75% |
| Operating Income | 109.30% | 89.48% | 86.78% | 80.72% | 75.52% |
| Income Before Tax | 101.30% | 71.75% | 70.21% | 81.66% | 76.07% |
| Income Tax Expenses | 115.20% | 121.60% | 62.96% | -71.76% | -168.87% |
| Earnings from Continuing Operations | 101.20% | 71.43% | 70.25% | 81.80% | 76.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 101.20% | 71.43% | 70.25% | 81.80% | 76.22% |
| EBIT | 109.30% | 89.48% | 86.78% | 80.72% | 75.52% |
| EBITDA | 161.96% | 110.85% | 99.67% | 88.62% | 81.96% |
| EPS Basic | 100.78% | 72.58% | 73.59% | 90.34% | 88.12% |
| Normalized Basic EPS | 115.46% | 80.66% | 79.08% | 81.71% | 81.69% |
| EPS Diluted | 100.37% | 72.51% | 73.54% | 90.33% | 88.11% |
| Normalized Diluted EPS | 115.05% | 80.66% | 79.08% | 81.71% | 81.69% |
| Average Basic Shares Outstanding | 6.92% | 6.26% | 10.67% | 27.35% | 51.85% |
| Average Diluted Shares Outstanding | 8.04% | 6.26% | 10.67% | 27.35% | 51.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |